Bicara Therapeutics (BCAX) Competitors $11.88 -0.70 (-5.56%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$11.89 +0.01 (+0.08%) As of 06/11/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. NAMS, BLTE, HRMY, KNSA, VCEL, DNLI, CGON, VERA, GMTX, and IMCRShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors NewAmsterdam Pharma Belite Bio Harmony Biosciences Kiniksa Pharmaceuticals Vericel Denali Therapeutics CG Oncology Vera Therapeutics Gemini Therapeutics Immunocore Bicara Therapeutics (NASDAQ:BCAX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends, community ranking and profitability. Do institutionals and insiders believe in BCAX or NAMS? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 15.5% of Bicara Therapeutics shares are held by company insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is BCAX or NAMS more profitable? Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A NewAmsterdam Pharma N/A N/A N/A Does the MarketBeat Community prefer BCAX or NAMS? NewAmsterdam Pharma received 14 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. Likewise, 90.91% of users gave NewAmsterdam Pharma an outperform vote while only 76.19% of users gave Bicara Therapeutics an outperform vote. CompanyUnderperformOutperformBicara TherapeuticsOutperform Votes1676.19% Underperform Votes523.81% NewAmsterdam PharmaOutperform Votes3090.91% Underperform Votes39.09% Do analysts rate BCAX or NAMS? Bicara Therapeutics presently has a consensus target price of $31.86, suggesting a potential upside of 168.17%. NewAmsterdam Pharma has a consensus target price of $43.00, suggesting a potential upside of 109.76%. Given Bicara Therapeutics' higher possible upside, equities analysts clearly believe Bicara Therapeutics is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, BCAX or NAMS? Bicara Therapeutics has higher earnings, but lower revenue than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/AN/AN/AN/ANewAmsterdam Pharma$47.14M48.82-$176.94M-$1.88-10.90 Does the media refer more to BCAX or NAMS? In the previous week, NewAmsterdam Pharma had 19 more articles in the media than Bicara Therapeutics. MarketBeat recorded 31 mentions for NewAmsterdam Pharma and 12 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.10 beat NewAmsterdam Pharma's score of 0.53 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 10 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNewAmsterdam Pharma beats Bicara Therapeutics on 6 of the 9 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$647.89M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E RatioN/A8.7827.1720.06Price / SalesN/A255.64409.72157.10Price / CashN/A65.8538.2534.64Price / BookN/A6.557.064.70Net IncomeN/A$143.93M$3.23B$247.88M7 Day Performance7.71%3.97%2.89%2.66%1 Month Performance-16.28%11.32%9.06%6.40%1 Year PerformanceN/A4.20%31.40%14.07% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics2.3353 of 5 stars$11.88-5.6%$31.86+168.2%N/A$647.89MN/A0.0032Positive NewsAnalyst RevisionNAMSNewAmsterdam Pharma2.9856 of 5 stars$18.93+4.5%$43.00+127.2%+3.2%$2.13B$47.14M-10.074Trending NewsAnalyst ForecastAnalyst RevisionBLTEBelite Bio2.2911 of 5 stars$65.02+0.2%$96.67+48.7%+25.2%$2.07BN/A-58.5810Short Interest ↑Analyst RevisionHRMYHarmony Biosciences4.7728 of 5 stars$35.56+3.1%$53.00+49.0%+18.4%$2.04B$744.85M16.85200Positive NewsShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals3.2478 of 5 stars$27.92+2.0%$38.80+39.0%+61.1%$2.04B$481.17M-199.41220Trending NewsInsider TradeVCELVericel2.67 of 5 stars$40.46-2.0%$61.14+51.1%+2.0%$2.04B$238.54M674.45300Positive NewsHigh Trading VolumeDNLIDenali Therapeutics4.3524 of 5 stars$13.96+5.4%$33.71+141.5%-29.7%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionHigh Trading VolumeCGONCG Oncology2.4986 of 5 stars$26.59+3.8%$58.22+119.0%-25.6%$2.03B$662K-17.6161Positive NewsAnalyst RevisionVERAVera Therapeutics2.8949 of 5 stars$31.74+67.5%$65.00+104.8%-42.5%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionGap UpHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+33.6%$2.02BN/A-46.6830High Trading VolumeIMCRImmunocore2.9124 of 5 stars$38.65+5.6%$58.89+52.4%-13.5%$1.94B$333.58M-40.68320Positive NewsAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies NAMS Competitors BLTE Competitors HRMY Competitors KNSA Competitors VCEL Competitors DNLI Competitors CGON Competitors VERA Competitors GMTX Competitors IMCR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCAX Stock Free BCAX Stock Alerts